# Transplantation and Cellular Therapy

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/transplantation-and-cellular-therapy/

## Facts

| Field | Value |
| --- | --- |
| Open Access | false |
| ISSN-L | 1083-8791 |
| ISSNs | 1083-8791,1523-6536,2666-6367 |
| OpenAlex ID | https://openalex.org/S59987174 |
| Publisher | Elsevier BV |

## Journal papers

Showing 12 of 37.

- [National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report](https://scholariq.org/papers/national-institutes-of-health-consensus-development-project-on-criteria-for/)
- [Current Use of and Trends in Hematopoietic Cell Transplantation in the United States](https://scholariq.org/papers/current-use-of-and-trends-in-hematopoietic-cell-transplantation-in-the-united/)
- [Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research](https://scholariq.org/papers/increasing-incidence-of-chronic-graft-versus-host-disease-in-allogeneic/)
- [Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation](https://scholariq.org/papers/indications-for-autologous-and-allogeneic-hematopoietic-cell-transplantation/)
- [Recommended Screening and Preventive Practices for Long-Term Survivors after Hematopoietic Cell Transplantation](https://scholariq.org/papers/recommended-screening-and-preventive-practices-for-long-term-survivors-after/)
- [Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells](https://scholariq.org/papers/late-events-after-treatment-with-cd19-targeted-chimeric-antigen-receptor/)
- [Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia](https://scholariq.org/papers/stable-mixed-hematopoietic-chimerism-after-bone-marrow-transplantation-for/)
- [A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality](https://scholariq.org/papers/a-refined-risk-score-for-acute-graft-versus-host-disease-that-predicts-response/)
- [Outcome of Transplantation for Myelofibrosis](https://scholariq.org/papers/outcome-of-transplantation-for-myelofibrosis/)
- [Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients](https://scholariq.org/papers/treatment-of-graft-versus-host-disease-with-mesenchymal-stromal-cells-a-phase-i/)
- [Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy](https://scholariq.org/papers/standardizing-definitions-of-hematopoietic-recovery-graft-rejection-graft/)
- [Hematopoietic Cell Transplantation as Curative Therapy for Idiopathic Myelofibrosis, Advanced Polycythemia Vera, and Essential Thrombocythemia](https://scholariq.org/papers/hematopoietic-cell-transplantation-as-curative-therapy-for-idiopathic/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.